When it comes to sourcing medicines for Acute Myeloid Leukemia (AML), a supply partner with experience is imperative. At CSI, we’ve built a reputation as a world leader in delivering reliable and timely supply solutions that help drive AML studies forward. Our expertise spans across numerous global AML programs, partnering with leading pharmaceutical and biotech companies to ensure that clinical trials are never delayed due to supply chain challenges. With direct manufacturer

Request: CSI was tasked with sourcing a vast quantity of Venetoclax and Azacitidine for a large pharmaceutical company's global study on Acute Myeloid Leukaemia, covering 17 countries in 3 continents. Challenge: The client needed to enroll patients within an extremely short timeframe of 6-months. Additionally, due to the global nature of the study, they also required Certificates of Analysis (CoA), making the feasibility of the request extra challenging. Solution: Leveragi